UroGen Pharma price target raised to $60 from $54 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on UroGen Pharma to $60 from $54 and keeps a Buy rating on the shares. The company announced positive long-term data from the pivotal ENVISION trial of UGN-102 in low-grade, intermediate-risk non-muscle-invasive bladder cancer, the analyst tells investors in a research note. The firm says the key metric was maintenance of complete response status in 82.3% of patients who were complete responders at the three-month time point. It increased its probability of approval for UGN-102 to 85% from 80%.